DBV Technologies S.A. - American Depositary Shares (DBVT)

4.1950Last Price

+0.0750 (1.82%)Change

Dbv Technologies is a biopharmaceutical company focused on developing innovative therapies for patients with food allergies, particularly peanut allergies

Utilizing its proprietary Systemic Immunotherapy platform, the company aims to create treatments that help desensitize individuals to allergens, ultimately enhancing their quality of life and reducing the risk of severe allergic reactions. By leveraging advanced medical technology and a rigorous clinical development approach, Dbv Technologies strives to bring novel, breakthrough solutions to the field of immunotherapy for food allergies.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationChâtillon, France, January 13, 2025

By DBV Technologies S.A. · Via GlobeNewswire · January 13, 2025

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

Châtillon, France, January 8th, 2025

By DBV Technologies S.A. · Via GlobeNewswire · January 8, 2025

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Châtillon, France, December 11th, 2024

By DBV Technologies S.A. · Via GlobeNewswire · December 11, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

By DBV Technologies S.A. · Via GlobeNewswire · December 2, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

Châtillon, France, November 11, 2024

By DBV Technologies S.A. · Via GlobeNewswire · November 11, 2024

DBV Technologies Reports Third Quarter 2024 Financial Results

Châtillon, France, November 6, 2024

By DBV Technologies S.A. · Via GlobeNewswire · November 6, 2024

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

Investors in healthcare and biotech sectors should keep an eye on several prominent companies making strides in innovation, clinical trials, and global expansion. Modular Medical (NASDAQMODD), Cardiol Therapeutics NASDAQ: CRDLNASDAQCRDL)(NASDAQ: DBVTNASDAQDBVT , and Virax Biolabs (NASDAQ: VRAXNASDAQ) are key players to watch in the ever-evolving medical landscape. Each company has announced significant developments in technology, trials, and product distribution, solidifying their positions in the market.

Via AB Newswire · October 23, 2024

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Châtillon, France, October 22, 2024

By DBV Technologies S.A. · Via GlobeNewswire · October 22, 2024

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Châtillon, France, October 18, 2024

By DBV Technologies S.A. · Via GlobeNewswire · October 18, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

By DBV Technologies S.A. · Via GlobeNewswire · October 14, 2024

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Châtillon, France, September 23, 2024

By DBV Technologies S.A. · Via GlobeNewswire · September 23, 2024